Jasper Therapeutics Inc. (JSPR)

2026-07-16T21:45:10.000Z - 14 days ago

Jasper Therapeutics trading resumes

2026-07-16T21:25:20.000Z - 14 days ago

Jasper Therapeutics completes acquisition of Kira Pharmaceuticals

Jul 16, 2026, 5:15 PM EDT - 14 days ago

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

2026-07-16T21:10:11.000Z - 14 days ago

Jasper Therapeutics trading halted, news pending

Jun 15, 2026, 8:00 AM EDT - 6 weeks ago

Jasper Therapeutics Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 6 weeks ago

Jasper Therapeutics Proxy statement: Proxy filing

2026-06-01T12:26:26.000Z - 2 months ago

Jasper Therapeutics initiates review of strategic alternatives

Jun 1, 2026, 8:00 AM EDT - 2 months ago

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

2026-05-15T13:18:13.000Z - 2 months ago

Jasper Therapeutics price target lowered to $3 from $4 at RBC Capital

2026-05-15T09:40:09.000Z - 2 months ago

Jasper Therapeutics downgraded to Hold from Buy at TD Cowen

May 14, 2026, 4:05 PM EDT - 2 months ago

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 7:00 AM EDT - 2 months ago

Jasper Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 2 months ago

Jasper Therapeutics Earnings release: Q1 2026

2026-04-01T11:59:40.000Z - 4 months ago

Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI

2026-03-30T20:37:13.000Z - 4 months ago

Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)

Mar 30, 2026, 4:30 PM EDT - 4 months ago

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Mar 30, 2026, 7:00 AM EDT - 4 months ago

Jasper Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 4 months ago

Jasper Therapeutics Annual report: Q4 2025

2026-03-23T10:20:58.000Z - 4 months ago

Jasper Therapeutics assumed with a Neutral at UBS

Mar 2, 2026, 3:50 PM EST - 5 months ago

Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 5 months ago

Jasper Therapeutics Slides: Corporate presentation

Feb 24, 2026, 4:30 PM EST - 5 months ago

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

2026-01-13T20:20:15.000Z - 7 months ago

Jasper Therapeutics initiated with a Buy at Rodman & Renshaw

Jan 8, 2026, 8:00 AM EST - 7 months ago

Jasper Therapeutics Transcript: Study Result

Jan 8, 2026, 8:00 AM EST - 7 months ago

Jasper Therapeutics Press release: Study Result

Jan 8, 2026, 8:00 AM EST - 7 months ago

Jasper Therapeutics Slides: Study Result

2026-01-08T12:15:17.000Z - 7 months ago

Jasper Therapeutics reports updated data from briquilimab studies

Jan 8, 2026, 7:00 AM EST - 7 months ago

Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

2026-01-07T21:35:34.000Z - 7 months ago

Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO

Jan 7, 2026, 4:30 PM EST - 7 months ago

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

2025-12-04T16:57:00.000Z - 8 months ago

3 Penny Stocks to Watch Now, 12/4/25

BQ

Dec 3, 2025, 3:00 PM EST - 8 months ago

Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Transcript: Study Result

Dec 2, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Press release: Study Result

Dec 2, 2025, 8:00 AM EST - 8 months ago

Jasper Therapeutics Slides: Study Result

2025-12-02T12:10:33.000Z - 8 months ago

Jasper Therapeutics reports data from ETESIAN Phase 1b study

Dec 2, 2025, 7:00 AM EST - 8 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 8 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 12, 2025, 3:30 PM EST - 9 months ago

Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 11, 2025, 4:00 PM EST - 9 months ago

Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 7:00 AM EST - 9 months ago

Jasper Therapeutics Slides: Investor Presentation

2025-11-10T13:05:12.000Z - 9 months ago

Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)

Nov 10, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics Earnings release: Q3 2025

Nov 9, 2025, 6:00 PM EST - 9 months ago

Jasper Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 8:00 AM EST - 9 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Sep 22, 2025, 1:05 PM EDT - 11 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

2025-09-22T10:55:06.000Z - 11 months ago

Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP

2025-09-19T10:00:28.000Z - 11 months ago

Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43

Sep 19, 2025, 12:07 AM EDT - 11 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

2025-09-18T20:15:24.000Z - 11 months ago

Jasper Therapeutics announces common stock offering, no amount given

Sep 18, 2025, 4:08 PM EDT - 11 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 3, 2025, 1:00 PM EDT - 11 months ago

Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 6:00 PM EDT - 11 months ago

Jasper Therapeutics Slides: Corporate Presentation

2025-08-15T11:35:55.000Z - 1 year ago

Jasper Therapeutics price target lowered to $25 from $29 at UBS

2025-08-13T20:35:13.000Z - 1 year ago

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Quarterly report: Q2 2025

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Press release: Study Update

Jul 7, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Slides: Study Update

Jul 7, 2025, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 24, 2025, 8:30 AM EDT - 1 year ago

Jasper Therapeutics Slides: Investor Presentation

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Status Update

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Status Update

Jun 14, 2025, 10:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 21, 2025, 11:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 4:05 PM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Jasper Therapeutics Quarterly report: Q1 2025

Mar 27, 2025, 12:30 PM EDT - 1 year ago

Jasper Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Registration statement: Registration Filing

Mar 3, 2025, 1:20 PM EST - 1 year ago

Jasper Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 1, 2025, 12:45 PM EST - 1 year ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q4 2024

Feb 25, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Transcript: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Press release: Study Update

Jan 8, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics Slides: Study Update

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 3, 2024, 3:25 PM EST - 1 year ago

Jasper Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 9:45 AM EST - 1 year ago

Jasper Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Quarterly report: Q3 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Transcript: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Press release: Study Result

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Slides: Study Result

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 20, 2024, 12:00 PM EDT - 2 years ago

Jasper Therapeutics Transcript: TD Cowen Chronic Urticaria Summit

Sep 17, 2024, 2:30 PM EDT - 2 years ago

Jasper Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 3:00 PM EDT - 2 years ago

Jasper Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 7:30 AM EDT - 2 years ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma